Log In
Print this Print this

KD019, XL647

  Manage Alerts
Collapse Summary General Information
Company Kadmon Corp. LLC
DescriptionReversible tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), VEGFR-2, VEGFR-3, and HER2/neu/ErbB2 receptor
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) ; Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Mechanism of ActionKinase inhibitor
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today